Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 2Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
vorasidenib × CNS × 90 days × Clear all
NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting
24 enrolled
CNS

Brain Neoplasms, Glioma

NCT06809322 2026-05-22

VIGOR

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
468 enrolled
CNS

Astrocytoma

NCT07547163 2026-04-23

LGG PRO's

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Recruiting
90 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡